[White Paper] Integrated Scientific Advice and Multiple Stakeholder Engagements
Ensuring the best chance of success for new technologies through development of evidence generation plans requires multi-stakeholder involvement with patients, [...]
NICE Talking to You: The Value of Early Scientific Advice
Starting in 2009, NICE became a pioneer among health technology assessment (HTA) agencies by offering the opportunity for early scientific [...]
The Disturbing Dearth of Evidence for Supportive Oncology
Despite historical reliance on evidence generated from randomized controlled trials (RCTs), there has been a surge in the number of [...]
ICER Launches New Podcast: A Prescription for Fair Drug Pricing
America’s got a fever. And the only prescription? More cowbell—and fair drug pricing. To that end, ICER announced the launch [...]
[White Paper] Health Technology Assessment During the COVID-19 Pandemic
The global COVID-19 pandemic currently permeates every aspect of daily life with long-lasting consequences for all sectors, including pharma and [...]
COVID-19 Vaccine Will Come At No Cost to Medicare Beneficiaries
Once approved, the Trump administration will cover COVID-19 vaccinations at no cost to Medicare beneficiaries. On Wednesday, CMS released an [...]
Evidence Forum Announces Fall Issue
Evidera’s biannual publication, Evidence Forum, explores the pressing scientific, strategic, and operational challenges of the current healthcare environment. The fall [...]
New Rule Requires Payers To Post Negotiated Rates, Cost-sharing Data
The Trump administration announced today that it has finalized a rule requiring private insurers to provide members with upfront prices negotiated [...]
AMI’s Specialty Pharmacy Database Enjoys Growing Accreditation Status
AMI’s Specialty Pharmacy Database recently gained accreditation status from four agencies: URAC, Accreditation Commission for Health Care (ACHC), The Center [...]
Bureaucrats May Stop Life-saving Meds from Reaching Canada
If Canadian bureaucrats on the Patent Medicine Prices Review Board (PMPRB) get their way, innovative new drugs and vaccines may not come [...]
How Can Payers Advance Patient-reported Measures in Oncology?
A newly published study explored patient-reported performance measures in oncology, the barriers to implementation, and actionable recommendations for public and [...]
Achieving Accurate Estimates of Shared Savings from Value-based Healthcare
This article is part of a series focused on calculating shared savings from value-based health care improvement solutions. There is [...]
[Podcast] Bruno Villetelle on Real World Data’s Role in Bringing Medication to Market
In this episode of Real World Talk, join host Emily Di Capua as she discusses the ways in which RWD [...]
[Virtual Summit] How much drug research will we sacrifice to save money?
Tune in to the 2020 STAT Summit On November 18th at 3:45pm ET for a robust discussion on the cost [...]
[Webinar] Putting Artificial Intelligence in R&D
Big Pharma and biotech are increasingly using artificial intelligence in drug discovery. Join a distinguished panel of experts on October [...]
ISPOR Invites Applications For President-Elect or Director
The ISPOR Nominations Committee is now inviting members to nominate themselves or a colleague or to serve as President-Elect or [...]
Value-based Care at Risk
An April survey by the National Association of ACOs showed that more than half the organizations in at-risk models planned [...]
Payers: The New Catalysts of Better Health
As health care delivery is getting more complex, the traditional definition of healthcare is evolving. This shift is necessitating the [...]
Trial Site Networks: Create Positive Change Through A Shift in Perspective
COVID-19 represents a stress test of sorts for our global healthcare system that will hopefully lead to positive changes over [...]
Patient Intelligence and Insights Reports Available from Self Care Catalysts
Patients negotiate a shifting landscape of goals and aspirations. They have to navigate unmet needs, barriers to care, influencers and [...]
Submit Your Abstracts for Virtual ISPOR 2021
Abstract Submissions Are Open for Virtual ISPOR 2021; May 17 – 20: "HEOR: Evolving for Tomorrow's Challenges" Submit under the [...]
Adaptive Trial Designs in Early Oncology
Our understanding of the genetic and molecular mechanisms that lead to cancer have improved greatly over the past decade thanks [...]
Bart Heeg on New Trends in HEOR
In this two-part blog series, Bart Heeg, Vice President HEOR and Founder at Ingress Health (A Cytel company) discusses trends [...]
Draft Scoping Document for the Assessment of Alzheimer’s Disease Posted by ICER
Yesterday the Institute for Clinical and Economic Review (ICER) posted a Draft Scoping Document detailing the planned review of the comparative clinical effectiveness [...]
FDA Approved NDA for KOSELUGO™ (selumetinib)
Recently the FDA approved AstraZeneca’s KOSELUGO™ (selumetinib) for treatment of pediatric patients two years of age and older with neurofibromatosis [...]